Cosmos Study October 14, 2025 Dual-Team Study Team A:Kersten Bartelt, RNEric Barkley Team B:Joel Jones, PharmDJoe Deckert, PhD Key Findings Among non-diabetic patients without chronic kidney disease (CKD), there was a minimal increase of 0.01 mg/dL to 0.02 mg/dL in serum creatinine in the months following initiation of semaglutide, liraglutide, or tirzepatide
What the Market Looks Like After Amino Asylum, Paradigm Peptides, and Peptide Sciences The post-shutdown research peptide market of 2026 is structurally different from 2024
July 23 BPC-157 Proposed use : ulcerative colitis (an inflammatory bowel disease) Outcome : Yes Margin : 8-6 in favor, with one abstention What the FDA was saying : There is a lack of evidence to support using
The real problem is not that weight returns
Because these medications mimic naturally occurring proteins, the side effect profile is low and generally well tolerated, unlike other weight loss medications that can cause heart and blood pressure issues
Food and Drug Administration (FDA) has been closely monitoring the safety of semaglutide and similar medications, particularly as their popularity has skyrocketed in recent months